Grifols Therapeutics, Inc., a leading global biotechnology company, is headquartered in the United States and operates extensively across Europe, Latin America, and Asia. Founded in 1909, Grifols has established itself in the biopharmaceutical industry, specialising in the development of innovative therapies derived from human plasma. The company’s core products include immunoglobulins, albumin, and clotting factors, which are essential for treating various medical conditions, including immune deficiencies and bleeding disorders. Grifols is renowned for its commitment to quality and safety, setting industry standards with its advanced manufacturing processes. With a strong market position, Grifols has achieved significant milestones, including the expansion of its global network of plasma collection centres. This strategic growth enhances its ability to deliver life-saving therapies to patients worldwide, solidifying its reputation as a trusted leader in the biopharmaceutical sector.
We don't have data for Grifols Therapeutics, Inc., but we can show you information about their parent organization instead.
View parent company